Physician profile
Deann E Dewitt
NPI 1386641108
$500.71
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $62.09 · 2021: $151.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $87.78 | 2019-2020 | |
| Adlon Therapeutics L.P. | $67.94 | 2019-2021 | |
| Cranial Technologies, INC | $58.73 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.23 | 2019-2021 | |
| Tris Pharma INC | $40.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $29.52 | 2020-2021 | |
| Glaxosmithkline, LLC. | $22.76 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $17.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.07 | 2019 | |
| Neos Therapeutics, LP | $14.02 | 2021 | |
| Shire North American Group INC | $13.33 | 2019 | |
| Intersect Ent, INC. | $12.06 | 2019 | |
| Sanofi Pasteur INC. | $11.67 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.55 | 2019 | |
| Novo Nordisk INC | $11.54 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $11.19 | 2019 | |
| Amgen INC. | $10.93 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deann Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.